ライフサイエンスコーパス: allogeneic

1 ients (236 autologous, 128 reduced-intensity allogeneic, 113 myeloablative allogeneic) underwent stan

2 ety and efficacy of autologous (auto) versus allogeneic (allo) bone marrow-derived hMSCs in NIDCM.

3 Whereas allogeneic (allo-)MSCs are immunoevasive, the capacity o

4 e Washington State residents (n = 1,792; 52% allogeneic and 90% hematologic malignancies) were freque

5 We demonstrated that both allogeneic and syngeneic CAR T cells show initial expans

6 trong graft-versus-leukemia (GVL) effects in allogeneic and xenogeneic murine GVHD models.

7 immune-stimulatory molecules including semi-allogeneic antigens from maternal cells, substances from

8 r, they differ markedly in their response to allogeneic antigens, strongly promoting regulatory T-cel

9 ion (MR1/Rapa/100 cGy) and transplanted with allogeneic B10.D2 (H2) BMC.

10 We found improved engraftment of fully allogeneic BALB/c islets in Micro capsules transplanted

11 treat graft-versus-host disease (GVHD) after allogeneic blood or marrow transplantation (alloBMT) put

12 es assessed the association of perioperative allogeneic blood transfusion, sepsis, and 5-year colon c

13 morrhage at cesarean section requires donor (allogeneic) blood transfusion.

14 Allogeneic BMC engraftment is enhanced with TGF-beta/Fc

15 Here, we demonstrate, using murine models of allogeneic BMT, that type 2 innate lymphoid cells (ILC2s

16 10/Fc, TGF-beta/Fc, or IL-2/Fc would enhance allogeneic bone marrow cell (BMC) engraftment and promot

17 The test group received allogeneic bone marrow MSCs by intradiscal injection of

18 reconstitution and thymus regeneration after allogeneic bone marrow nucleated cell transplantation bu

19 s-host disease (aGVHD) in 2 different murine allogeneic bone marrow transplant (BMT) models.

20 sm and allograft tolerance in mice receiving allogeneic bone marrow transplant (BMT) with minimal con

21 Allogeneic bone marrow transplant from an HLA-matched si

22 Allogeneic bone marrow transplantation (allo-BMT) is a c

23 st disease (GVHD), a serious complication of allogeneic bone marrow transplantation (allo-BMT).

24 is a major cause of late mortality following allogeneic bone marrow transplantation (BMT) and is char

25 Allogeneic bone marrow transplantation has been attempte

26 ompare the safety and efficacy of 2 doses of allogeneic bone marrow-derived human mesenchymal stem ce

27 hough the efficiency of diabetes reversal of allogeneic but not syngeneic CC islets was lower than th

28 erentiated derivatives are not recognized as allogeneic by CD8(+) T cells, do not bind anti-HLA antib

29 ng repeated i.v. administration of activated allogeneic canine MSC.

30 However, the use of allogeneic CAR T cells poses a concern in that it may in

31 ls, with a higher peak but rapid deletion of allogeneic CAR T cells.

32 represents a novel experience in humans with allogeneic cardiac stem cell in a rigorously imaging-bas

33 hether post-MI transendocardial injection of allogeneic CBSCs reduces pathological structural and fun

34 To understand the mechanism whereby allogeneic CD19 CAR T cells may mediate anti-lymphoma ac

35 and iDDC had a reduced ability to stimulate allogeneic CD4(+) T cells in the mixed-lymphocyte reacti

36 versial, potentially limiting the success of allogeneic cell combination therapy (ACCT).

37 progenitor cells are a bone marrow-derived, allogeneic, cell therapy product that modulates the immu

38 On the other hand, allogeneic cells show several advantages over autologous

39 /or epigenomic manipulation of autologous or allogeneic cells.

40 lecular patterns have been well defined, how allogeneic cellular stimuli evoke innate responses remai

41 te prolonged and high levels of multilineage allogeneic chimerism and robust tolerance to the donor.

42 SCs:CD4(+)T-cell suppression was assessed in allogeneic coculture systems.

43 Allogeneic corneal transplantation was performed on infl

44 nts with cDGS underwent transplantation with allogeneic cultured thymus.

45 mediated CD47 blockade in a syngeneic and an allogeneic DCD rat kidney transplant model.

46 ects extensive genetic polymorphisms between allogeneic donors and recipients, most prominently withi

47 f intranodal administration of autologous or allogeneic DRibbles together with anti-OX40 antibody led

48 ling evidence that these cells can recognize allogeneic entities and that they mediate graft rejectio

49 ted tumor-specific T-cell dysfunction in the allogeneic environment.

50 d safety of a single local administration of allogeneic expanded adipose-derived stem cells (Cx601) i

51 ng autoimmune inflammatory bowel disease and allogeneic graft-versus-host disease.

52 stem that allows them to respond directly to allogeneic grafts is a topic of much debate.

53 esults provide new mechanistic insights into allogeneic GVT, validate the importance of targeting the

54 Allogeneic haematopoietic stem cell transplantation has

55 potential long-term neurological benefit of allogeneic haematopoietic stem cell transplantation in a

56 t cerebral adrenoleukodystrophy treated with allogeneic haematopoietic stem cell transplantation on a

57 ring to guide dosing improves outcomes after allogeneic haemopoietic cell transplantation (HCT).

58 In allogeneic HCT (allo-HCT), donor-derived T cells recogni

59 Limited data also support use of allogeneic HCT (alloHCT) in selected HIV-infected patien

60 of multiple dsDNA viruses was frequent after allogeneic HCT and had a dose-dependent association with

61 ipient pairs (8638 subjects) who received an allogeneic HCT and had archived pre-HCT peripheral blood

62 spectively tested weekly plasma samples from allogeneic HCT recipients at our center from 2007 to 201

63 Reduced-intensity allogeneic HCT recipients showed evidence of delayed dec

64 Conclusion Myeloablative allogeneic HCT recipients showed significant cognitive d

65 Among 404 allogeneic HCT recipients, including 125 cord blood, 125

66 present in 18.7% of autologous and 35.7% of allogeneic HCT recipients.

67 gic malignancies who underwent autologous or allogeneic HCT to inpatient palliative care integrated w

68 center cohorts, with clinical outcomes after allogeneic HCT within this prospective, multicenter stud

69 fied biomarkers with clinical outcomes after allogeneic HCT.

70 ng correlate with higher risks of GVHD after allogeneic HCT.

71 enhance GVL while minimizing GVHD following allogeneic HCT.

72 ogeneic splenocyte immunization in vivo, and allogeneic heart transplantation.

73 The ability to distinguish allogeneic hematopoietic cell transplant (allo-HCT) reci

74 ronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant (HCT) conferred

75 clinical acute graft-versus-host disease in allogeneic hematopoietic cell transplant recipients.

76 Allogeneic hematopoietic cell transplantation (allo-HCT)

77 ins a major life-threatening complication of allogeneic hematopoietic cell transplantation (allo-HCT)

78 Allogeneic hematopoietic cell transplantation (allo-HCT)

79 se (GVHD), which is the main complication of allogeneic hematopoietic cell transplantation (allo-HCT)

80 f graft-versus-host disease (GVHD) following allogeneic hematopoietic cell transplantation (allo-HCT)

81 in double-stranded DNA (dsDNA) viruses after allogeneic hematopoietic cell transplantation (HCT) are

82 We analyzed patients treated with allogeneic hematopoietic cell transplantation (HCT) from

83 t-versus-host disease (GVHD) is higher after allogeneic hematopoietic cell transplantation (HCT) from

84 Purpose The optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT) is u

85 ase (GVHD) prophylaxis after matched-related allogeneic hematopoietic cell transplantation (HCT) rece

86 Allogeneic hematopoietic cell transplantation (HCT) repr

87 t-versus-host disease (GVHD) is common after allogeneic hematopoietic cell transplantation (HCT).

88 successful outcomes in patients who undergo allogeneic hematopoietic cell transplantation (HCT).

89 t cause of morbidity and mortality following allogeneic hematopoietic cell transplantation (HCT).

90 rment is well-recognized after myeloablative allogeneic hematopoietic cell transplantation (HCT).

91 treatment options for relapsed lymphoma post-allogeneic hematopoietic cell transplantation (post-allo

92 A major barrier to successful use of allogeneic hematopoietic cell transplantation is acute g

93 yclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the o

94 major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation.

95 safety and immunogenicity results of MVA in allogeneic hematopoietic stem cell transplant (HCT) reci

96 Autologous and allogeneic hematopoietic stem cell transplant (HSCT) pat

97 megalovirus (CMV) retinitis in the pediatric allogeneic hematopoietic stem cell transplant (HSCT) pop

98 is a respiratory virus detected in >/=9% of allogeneic hematopoietic stem cell transplant (HSCT) rec

99 with increased morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT).

100 ry bowel disease (IBD), and poor survival in allogeneic hematopoietic stem cell transplant recipients

101 f PIV3-specific T cells and viral control in allogeneic hematopoietic stem cell transplant recipients

102 onic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplant reflects a

103 mune responses can eradicate lymphomas after allogeneic hematopoietic stem cell transplantation (AHSC

104 is a frequent complication in recipients of allogeneic hematopoietic stem cell transplantation (allo

105 immunity, have been successfully treated by allogeneic hematopoietic stem cell transplantation (Allo

106 Allogeneic hematopoietic stem cell transplantation (allo

107 major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo

108 ental graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo

109 e of adult intestinal toxemia botulism in an allogeneic hematopoietic stem cell transplantation (allo

110 The graft-versus-leukemia (GVL) effect in allogeneic hematopoietic stem cell transplantation (allo

111 ngiogenesis has not been investigated during allogeneic hematopoietic stem cell transplantation (allo

112 Leukemia relapse remains the major cause of allogeneic hematopoietic stem cell transplantation (HCT)

113 e a frequent and devastating complication of allogeneic hematopoietic stem cell transplantation (HSCT

114 mes Foundation developed recommendations for allogeneic hematopoietic stem cell transplantation (HSCT

115 of morbidity and mortality in patients after allogeneic hematopoietic stem cell transplantation (HSCT

116 t important cause of treatment failure after allogeneic hematopoietic stem cell transplantation (HSCT

117 pstein-Barr virus (EBV) infections following allogeneic hematopoietic stem cell transplantation (HSCT

118 solid-organ transplants, virome dynamics in allogeneic hematopoietic stem cell transplantation (HSCT

119 relies largely on intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT

120 Allogeneic hematopoietic stem cell transplantation (HSCT

121 The outcome of allogeneic hematopoietic stem cell transplantation (HSCT

122 sus-host disease (GVHD) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT

123 Allogeneic hematopoietic stem cell transplantation (HSCT

124 Allogeneic hematopoietic stem cell transplantation (HSCT

125 Allogeneic hematopoietic stem cell transplantation (HSCT

126 e antigen (anti-HBc)-positive patients after allogeneic hematopoietic stem cell transplantation (HSCT

127 sease (cGVHD) is a notorious complication of allogeneic hematopoietic stem cell transplantation and c

128 th advanced systemic mastocytosis, including allogeneic hematopoietic stem cell transplantation and m

129 Clinical outcomes for patients undergoing allogeneic hematopoietic stem cell transplantation conti

130 rvival rates in patients treated early after allogeneic hematopoietic stem cell transplantation do no

131 s (PIDs) have been successfully treated with allogeneic hematopoietic stem cell transplantation for m

132 ent with acute myeloid leukemia who received allogeneic hematopoietic stem cell transplantation from

133 The thymus plays a key role post allogeneic hematopoietic stem cell transplantation in th

134 Allogeneic hematopoietic stem cell transplantation is ha

135 stress syndrome but has not been assessed in allogeneic hematopoietic stem cell transplantation recip

136 All allogeneic hematopoietic stem cell transplantation recip

137 On the contrary, long-term allogeneic hematopoietic stem cell transplantation recip

138 Therefore, allogeneic hematopoietic stem cell transplantation shoul

139 l membrane oxygenation within 240 days after allogeneic hematopoietic stem cell transplantation survi

140 The success of allogeneic hematopoietic stem cell transplantation, a ke

141 ell-mediated graft-versus-host disease after allogeneic hematopoietic stem cell transplantation, sugg

142 se-free survival may only be achievable with allogeneic hematopoietic stem cell transplantation.

143 s syndrome is a frequent condition following allogeneic hematopoietic stem cell transplantation.

144 n animal models of virally triggered IBD and allogeneic hematopoietic stem cell transplantation.

145 146 (interquartile range, 27-321) days after allogeneic hematopoietic stem cell transplantation.

146 ted with immune suppressants, etoposide, and allogeneic hematopoietic stem cell transplantation; more

147 Twenty-one recipients of allogeneic hematopoietic stem cell transplants who under

148 The use of allogeneic hematopoietic stem cells (HSCs) to treat gene

149 ment of cure rates for patients treated with allogeneic hematopoietic stem-cell transplantation (HSCT

150 t molecular subgroups of patients undergoing allogeneic hematopoietic stem-cell transplantation for M

151 yeloid leukemia (AML) can only be cured when allogeneic hematopoietic stem-cell transplantation induc

152 Seven responders (44%) proceeded to allogeneic hematopoietic stem-cell transplantation, incl

153 d minimal residual disease response, rate of allogeneic hematopoietic stem-cell transplantation, rela

154 function and death, can be halted only with allogeneic hematopoietic stem-cell transplantation.

155 utations may predict clinical outcomes after allogeneic hematopoietic stem-cell transplantation.

156 t of alloimmunity-induced autoimmunity after allogeneic hematopoietic transplantation.

157 ency are frequently related complications of allogeneic hematopoietic transplantation.

158 Purpose The major causes of mortality after allogeneic hematopoietic-cell transplantation (allo-HCT)

159 Most clinical allogeneic hemopoietic cell transplants (alloHCT) are no

160 t reactivity with myeloma patient sera after allogeneic HSCT and that may be significantly translocat

161 ge cerebral disease who were treated with an allogeneic HSCT and to identify disease- and treatment-r

162 pha-L-iduronidase, and patients treated with allogeneic HSCT at the onset have improved outcome, sugg

163 n's Hospital of Colorado (CHCO) who received allogeneic HSCT between January 2010 and December 2014.

164 ho were at least 16 years old, had undergone allogeneic HSCT for a hematological malignancy, and had

165 Among patients undergoing allogeneic HSCT for hematological malignancy, early admi

166 A total of 101 patients underwent allogeneic HSCT from January 2010 to December 2013; 32 (

167 These results establish a new preclinical allogeneic HSCT model for evaluation of GvHD prophylaxis

168 is significantly upregulated in the serum of allogeneic HSCT patients at aGVHD onset compared with no

169 recent cluster of CMV retinitis in pediatric allogeneic HSCT patients may suggest a rise in incidence

170 Among 297 allogeneic HSCT recipients, 85 (28.7%) were HBsAg-negati

171 The study cohort included 452 adult-allogeneic HSCT recipients, transplanted from 1997 to 20

172 ly in 1 045 peripheral blood samples from 98 allogeneic HSCT recipients.

173 tive to enzyme replacement therapy (ERT) and allogeneic HSCT that has shown clinical benefit for aden

174 atients with undetectable HBV DNA undergoing allogeneic HSCT were prospectively monitored every 4 wee

175 Both patients were successfully treated with allogeneic HSCT with sustained reconstitution of hematop

176 ts had a high rate of HBV reactivation after allogeneic HSCT, with determinants of HBV reactivation i

177 improve airflow decline-free survival after allogeneic HSCT.

178 ysiologically relevant, preclinical model of allogeneic HSCT.

179 2014 to December 2014, 28 patients underwent allogeneic HSCT; 13 patients (46%) had CMV viremia, not

180 epidemiology of pre-engraftment GNB in 1118 allogeneic HSCTs (allo-HSCTs) and 1625 autologous HSCTs

181 y, and efficacy of intracoronary delivery of allogeneic human cardiac stem cell in 55 patients with l

182 rica to determine the safety and efficacy of allogeneic human mesenchymal stem cells (MSCs) in reduci

183 ther 20 million (n=15) or 100 million (n=15) allogeneic human mesenchymal stem cells via transendocar

184 the reverse was true when the autologous and allogeneic IgG concentrations were augmented in allograf

185 Allogeneic immune cells, particularly T cells in donor g

186 text, we were able to visualize differential allogeneic immune synapse formation in polyclonal CD4(+)

187 In contrast, the vasculature of DSA-exposed allogeneic islet grafts was devoid of lesions because sp

188 Ablation of HSCs impaired tolerance to allogeneic islet transplants in B6 recipients.

189 in MicroMix capsules improved engraftment of allogeneic islets in the IP site, but resulted deleterio

190 bated with T cells that were stimulated with allogeneic leukocytes or CD3/CD28 cross-linking.

191 Using a fully allogeneic mismatched (BALB/c to C57BL/6) murine aortic

192 dentified upon T cell stimulation and during allogeneic MLR.

193 r-lateral left ventricular wall in C57BL/6J (allogeneic model, n = 17) and C3H (syngeneic model, n =

194 (REG)-dependent protection against IRI in an allogeneic mouse model.

195 In vitro, allogeneic mouse MSCs inhibited MRL.Fas(lpr) T cell prol

196 Allogeneic MSC therapy may be a valid alternative for th

197 nt here a randomized, controlled trial using allogeneic MSC, which are logistically more convenient t

198 AKI after cardiac surgery, administration of allogeneic MSCs did not decrease the time to recovery of

199 Autologous, NCT00968760; allogeneic, NCT01497184; long-term follow-up, NCT0149203

200 jor histocompatibility complex (MHC)-matched allogeneic neural cell grafting in the brain, which is c

201 ZA) and decitabine (DAC) in combination with allogeneic NK cells generated from CD34(+) hematopoietic

202 In the setting of allogeneic nonmyeloablative HSC transplants (HSCTs), sta

203 ognitive functioning after reduced-intensity allogeneic or autologous HCT remains unclear.

204 ls (RBC) isolated from knockout swine and to allogeneic or autologous human RBC.

205 had been immune rejections and responses of allogeneic or autologous stem cells.

206 were collected from draining lymph nodes of allogeneic or syngeneic corneal transplanted BALB/c mice

207 hestrate immune responses and destruction of allogeneic organ transplants, but how this process is re

208 3 patients with Ph(+) ALL with autologous or allogeneic (p190)BCR-ABL-specific CTLs.

209 -mediated skin injury caused by transferring allogeneic peripheral blood mononuclear cells more effec

210 Lack of immune cell penetration and T cell allogeneic priming was observed.

211 hronic disease complications and for whom an allogeneic procedure could present an unacceptable risk.

212 an antibody binding than human blood group O allogeneic RBC in 22% of tested sera.

213 ripotent stem cell (PSC)-derived products in allogeneic recipients.

214 ys for autologous recipients and 51 days for allogeneic recipients.

215 andard-issue (oldest available), compatible, allogeneic red cells (long-term storage group).

216 e either the freshest available, compatible, allogeneic red cells (short-term storage group) or stand

217 analysis using the Luminex platform, T cell allogeneic responses were measured by flow cytometry, an

218 e IDO-1 score (p = 0.007) and not undergoing allogeneic SCT (p = 0.007) was found to significantly pr

219 Of 349 patients who underwent allogeneic SCT during the study period, 92 patients (26%

220 asive monitoring of treatment response after allogeneic SCT for myelofibrosis.

221 In patients with an available donor, allogeneic SCT may also be considered.

222 of platelet counts among patients undergoing allogeneic SCT or chemotherapy and because platelet tran

223 assess prognostic factors of survival in all allogeneic SCT recipients admitted to the ICU between 20

224 Early mortality of allogeneic SCT recipients admitted to the ICU is especia

225 earing CMV tet(low) and tet(high) CTLs after allogeneic SCT.

226 t increasing the CMV reactivation risk after allogeneic SCT.

227 enitors, but fails to mobilize 33% of normal allogeneic sibling donors in 1 apheresis.

228 by a phase 2 efficacy trial was conducted in allogeneic sibling donors.

229 d primary human B cells as well as in murine allogeneic skin transplant and alloantigen-induced T cel

230 esponses to allogeneic stimulation in vitro, allogeneic splenocyte immunization in vivo, and allogene

231 Immunization with allogeneic splenocytes in vivo resulted in increased all

232 with leukemia who receive a T cell-depleted allogeneic stem cell graft followed by postponed donor l

233 graftment with a normal human donor to model allogeneic stem cell rescue.

234 IDO-1 score (p < 0.0001) and not undergoing allogeneic stem cell transplant (SCT, p = 0.0005) predic

235 ents, 4 received consolidative hematopoietic allogeneic stem cell transplant, and 9 (9% of all enroll

236 study of 114 consecutive patients undergoing allogeneic stem cell transplant.

237 Chronic graft-vs-host-disease (cGVHD) after allogeneic stem cell transplantation (AHSCT) may resembl

238 ng 1 documented case of HIV-1 cure following allogeneic stem cell transplantation (allo-SCT), several

239 ate nonrelapse mortality and morbidity after allogeneic stem cell transplantation (allo-SCT).

240 of nonrelapse morbidity and mortality after allogeneic stem cell transplantation (allo-SCT).

241 1m MRD may be used as a predictive factor of allogeneic stem cell transplantation (ASCT) benefit.

242 Allogeneic stem cell transplantation (SCT) has been prop

243 ge and after censoring patients who received allogeneic stem cell transplantation (SCT) in first remi

244 Admission of allogeneic stem cell transplantation (SCT) recipients to

245 V reactivation is a major complication after allogeneic stem cell transplantation (SCT).

246 consider additional studies and referral for allogeneic stem cell transplantation are also discussed.

247 Donors for allogeneic stem cell transplantation are preferentially

248 Allogeneic stem cell transplantation has the possibility

249 e of pathological immune responses following allogeneic stem cell transplantation resulting in acute

250 nitored 39 children shortly before and after allogeneic stem cell transplantation twice weekly by use

251 disease (cGVHD) is a serious complication of allogeneic stem cell transplantation with few effective

252 123) and DC-SIGN (rs11465384 and rs7248637), allogeneic stem cell transplantation, respiratory virus

253 nogenic significance after HLA 10/10 matched allogeneic stem cell transplantation, we show that in th

254 common complication for patients undergoing allogeneic stem cell transplantation.

255 e of morbidity and mortality from GVHD after allogeneic stem cell transplantation.

256 The only curative option for CMML remains allogeneic stem cell transplantation.

257 elevated bleeding risk in patients receiving allogeneic stem cell transplants (SCTs) or chemotherapy

258 nditioning may reduce the rate of relapse in allogeneic stem cell transplants.

259 first remission and no identified donor for allogeneic stem-cell transplantation (SCT) were eligible

260 MRI, had withdrawn from the study to undergo allogeneic stem-cell transplantation and later died from

261 ; 95% CI, 58.7% to 73.2%; P = 0.33) and that allogeneic stem-cell transplantation had a beneficial ef

262 y may be a safe and effective alternative to allogeneic stem-cell transplantation in boys with early-

263 ctory graft-versus-host disease (GVHD) after allogeneic stem-cell transplantation.

264 for adult and pediatric patients undergoing allogeneic stem-cell transplantation.

265 e patients in each treatment group underwent allogeneic stem-cell transplantation.

266 n of death in patients with acute GVHD after allogeneic stem-cell transplantation.

267 with acute GVHD who had received consecutive allogeneic stem-cell transplantation.

268 ced obesity and assessed immune responses to allogeneic stimulation in vitro, allogeneic splenocyte i

269 D70 serves as a unique negative regulator of allogeneic T cell response by contributing to donor T ce

270 ing role of BECs in a human ex vivo model of allogeneic T cell response, both in healthy subjects and

271 CD1(-) cDC were superior in stimulating allogeneic T cell responses and in cross-presenting vira

272 cause of its high permselectivity and strong allogeneic T cell responses.

273 among patients in their ability to suppress allogeneic T cells and in the use of either IL-17/argina

274 Donor-derived allogeneic T cells evoke potent graft versus tumor (GVT)

275 Allogeneic T cells from corneal transplant hosts promote

276 Allogeneic T cells from high-risk (HR) grafted mice indu

277 teins enabling subsequent ex vivo priming of allogeneic T cells with a specific cytokine signature.

278 direct antiproliferative effects of AzaC on allogeneic T cells.

279 Collectively, our data implicate Cdk5 in allogeneic T-cell responses after HCT and as an importan

280 histocompatibility complex class II reduces allogeneic T-cell responses in vitro and in vivo.

281 Thus, adoptive transfer of allogeneic T9IL-33 cells offers an attractive approach f

282 Murine DSAs bound to allogeneic targets expressed by islet cells and induced

283 ch a drug product (CTX-DP) was developed for allogeneic therapy.

284 During allogeneic tissue transplantation, the inhibition of lym

285 nomodulation may underlie the association of allogeneic transfusion with increased perioperative morb

286 rogate for NETs in 103 consecutive pediatric allogeneic transplant recipients at day 0, +14, +30, +60

287 Mice that received allogeneic transplant showed an increase in nuclear 5-LO

288 highly educated patients more often received allogeneic transplantation (16.3% v 8.7%).

289 nts with hematologic malignancies undergoing allogeneic transplantation (alloSCT), but its prognostic

290 loablative conditioning regimen (MAC) before allogeneic transplantation in patients with myelodysplas

291 ngiogenesis occurred as early as day+2 after allogeneic transplantation mainly in GVHD typical target

292 Allogeneic transplantation of foreign organs or tissues

293 stitution is abrogated in both syngeneic and allogeneic transplantation using Treg-depleted mice as r

294 Allogeneic transplantation was allowed.

295 We compared treatment intensity, allogeneic transplantation, and response rates by educat

296 In the mouse model of corneal allogeneic transplantation, galectin-8-induced lymphangi

297 D) is the primary nonrelapse complication of allogeneic transplantation, understanding of its pathoge

298 elopment of typical microvascular lesions in allogeneic transplants.

299 uced-intensity allogeneic, 113 myeloablative allogeneic) underwent standardized neuropsychologic test

300 ed four isogeneic (Lewis-to-Lewis) and seven allogeneic (Wistar-to-Lewis) ATx procedures.